Gekko Brief
AI summaryNov 9 close
This week's news is dominated by a wave of securities-law investigation announcements from multiple law firms, including Kaplan Fox, SBS Law, and Kessler Topaz Meltzer & Check, following a whistleblower complaint alleging that Madrigal suppressed adverse liver-injury findings and presented unreproducible efficacy data for Rezdiffra. The complaint concerns the safety and efficacy data underlying the drug. Separately, Madrigal's Q3 2026 results, reported 3 November, showed net sales of $431 million, up 50% year-over-year, with year-to-date sales crossing $1 billion and annualizing at over $1.7 billion, while active Rezdiffra patients reached 55,850 versus 29,500 a year earlier.
MDGL closed at $432.79, up 8.3% on the day but down 8.3% over one month and 19.1% over three months, sitting below both its 50-day ($484.73) and 200-day ($497.36) averages. The GekkoIndex reads 69.2, placing the stock in the Accumulation zone, while the price sits 42.7% below Gekko Fair Value of $754.69.
Earnings are not due until 18 February 2027, 100 days out, keeping that catalyst outside a typical 20-day hold. Smart money activity over the last 90 days shows 5 insider purchases alongside an insider sale by General Counsel Kelley and a Form 4 filing from Baker Bros. Advisors; unusual options activity in the last 30 days shows 1 signal, with put premium of $666,520 against call premium of $398,090. Seasonality from this point has averaged +10.5% over 20 trading days across 5 years, rising in 3 of them.